Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01112306
Registration number
NCT01112306
Ethics application status
Date submitted
8/04/2010
Date registered
28/04/2010
Date last updated
8/12/2023
Titles & IDs
Public title
ACT-293987 in Pulmonary Arterial Hypertension
Query!
Scientific title
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of ACT-293987 in Patients With Pulmonary Arterial Hypertension
Query!
Secondary ID [1]
0
0
2009-014992-31
Query!
Secondary ID [2]
0
0
AC-065A303
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pulmonary Arterial Hypertension
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Cardiovascular
0
0
0
0
Query!
Hypertension
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - ACT-293987
Experimental: 1 - ACT-293987, twice daily
Treatment: Drugs: ACT-293987
Tablets, twice daily
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Treatment-emergent Adverse Events (TEAEs) up to 3 Days After Study Intervention Discontinuation
Query!
Assessment method [1]
0
0
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug.
Query!
Timepoint [1]
0
0
Up to 3 days after study drug discontinuation (Up to 10.5 years)
Query!
Primary outcome [2]
0
0
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 3 Days After Study Intervention Discontinuation
Query!
Assessment method [2]
0
0
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. Those SAEs occurring during study drug administration, that is, between study drug initiation and three days after study drug discontinuation, are defined as treatment-emergent SAEs.
Query!
Timepoint [2]
0
0
Up to 3 days after study drug discontinuation (Up to 10.5 years)
Query!
Primary outcome [3]
0
0
Number of Participants With TEAEs Leading to Permanent Discontinuation of Study Intervention
Query!
Assessment method [3]
0
0
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug.
Query!
Timepoint [3]
0
0
Up to 10.5 years
Query!
Secondary outcome [1]
0
0
Percentage of Alive Participants
Query!
Assessment method [1]
0
0
Percentage of alive participants were analyzed using Kaplan-Meier (KM) estimates.
Query!
Timepoint [1]
0
0
Baseline (Day 1), Months 3, 6, 9, 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Query!
Eligibility
Key inclusion criteria
* Patients who participated to the double-blind study AC-065A302 and either had a morbidity event or had completed the study as scheduled per protocol.
* Signed informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Patients who have started receiving prostacyclin (epoprostenol) or prostacyclin analogs (i.e., treprostinil, iloprost, beraprost) since the last study drug intake in AC-065A302/GRIPHON.
* Severe hepatic impairment (Child-Pugh C).
* Females who are pregnant or who plan to become pregnant during the study, or are breastfeeding.
* Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence, or psychiatric disease.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/07/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
26/08/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
709
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Adelaide
Query!
Recruitment hospital [2]
0
0
- Bedford Park
Query!
Recruitment hospital [3]
0
0
- Chermside
Query!
Recruitment hospital [4]
0
0
- Concord
Query!
Recruitment hospital [5]
0
0
- Darlinghurst
Query!
Recruitment hospital [6]
0
0
- Fitzroy
Query!
Recruitment hospital [7]
0
0
- Hobart
Query!
Recruitment hospital [8]
0
0
- Murdoch
Query!
Recruitment hospital [9]
0
0
- New Lambton
Query!
Recruitment hospital [10]
0
0
- Parkville
Query!
Recruitment postcode(s) [1]
0
0
- Adelaide
Query!
Recruitment postcode(s) [2]
0
0
- Bedford Park
Query!
Recruitment postcode(s) [3]
0
0
- Chermside
Query!
Recruitment postcode(s) [4]
0
0
- Concord
Query!
Recruitment postcode(s) [5]
0
0
- Darlinghurst
Query!
Recruitment postcode(s) [6]
0
0
- Fitzroy
Query!
Recruitment postcode(s) [7]
0
0
- Hobart
Query!
Recruitment postcode(s) [8]
0
0
- Murdoch
Query!
Recruitment postcode(s) [9]
0
0
- New Lambton
Query!
Recruitment postcode(s) [10]
0
0
- Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Delaware
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Indiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Iowa
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kansas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kentucky
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Louisiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maryland
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Massachusetts
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Michigan
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Minnesota
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Missouri
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Jersey
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New York
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
North Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Ohio
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Oregon
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Pennsylvania
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Tennessee
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Texas
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Virginia
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Wisconsin
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
Buenos Aires
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Cordoba
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Corrientes
Query!
Country [29]
0
0
Austria
Query!
State/province [29]
0
0
Graz
Query!
Country [30]
0
0
Austria
Query!
State/province [30]
0
0
Vienna
Query!
Country [31]
0
0
Belarus
Query!
State/province [31]
0
0
Minsk
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Brussels
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Leuven
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Alberta
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
British Columbia
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Manitoba
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Ontario
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Quebec
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Saskatchewan
Query!
Country [40]
0
0
Chile
Query!
State/province [40]
0
0
Santiago De Chile
Query!
Country [41]
0
0
China
Query!
State/province [41]
0
0
Beijing
Query!
Country [42]
0
0
China
Query!
State/province [42]
0
0
Guangzhou
Query!
Country [43]
0
0
China
Query!
State/province [43]
0
0
Shanghai
Query!
Country [44]
0
0
Colombia
Query!
State/province [44]
0
0
Bogota
Query!
Country [45]
0
0
Czechia
Query!
State/province [45]
0
0
Praha 2
Query!
Country [46]
0
0
Denmark
Query!
State/province [46]
0
0
Arhus
Query!
Country [47]
0
0
Denmark
Query!
State/province [47]
0
0
Copenhagen
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Bron Cedex
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Le Kremlin-Bicetre Cedex
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Lille Cedex
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Toulouse Cedex 9
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Berlin
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Dresden
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Giessen
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Greifswald
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Hannover
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Heidelberg
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Köln
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Leipzig
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Löwenstein
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Regensburg
Query!
Country [62]
0
0
Greece
Query!
State/province [62]
0
0
Alexandroupoli
Query!
Country [63]
0
0
Greece
Query!
State/province [63]
0
0
Athens
Query!
Country [64]
0
0
Greece
Query!
State/province [64]
0
0
Thessaloniki
Query!
Country [65]
0
0
Hungary
Query!
State/province [65]
0
0
Budapest
Query!
Country [66]
0
0
Hungary
Query!
State/province [66]
0
0
Debrecen
Query!
Country [67]
0
0
Hungary
Query!
State/province [67]
0
0
Pecs
Query!
Country [68]
0
0
Hungary
Query!
State/province [68]
0
0
Szeged
Query!
Country [69]
0
0
India
Query!
State/province [69]
0
0
Ahmedabad
Query!
Country [70]
0
0
India
Query!
State/province [70]
0
0
Chennai
Query!
Country [71]
0
0
India
Query!
State/province [71]
0
0
Hyderabad
Query!
Country [72]
0
0
Ireland
Query!
State/province [72]
0
0
Dublin
Query!
Country [73]
0
0
Israel
Query!
State/province [73]
0
0
Haifa
Query!
Country [74]
0
0
Israel
Query!
State/province [74]
0
0
Jerusalem
Query!
Country [75]
0
0
Israel
Query!
State/province [75]
0
0
Petah Tikva
Query!
Country [76]
0
0
Israel
Query!
State/province [76]
0
0
Rehovot
Query!
Country [77]
0
0
Israel
Query!
State/province [77]
0
0
Tel Aviv
Query!
Country [78]
0
0
Israel
Query!
State/province [78]
0
0
Tel-Hashomer
Query!
Country [79]
0
0
Korea, Republic of
Query!
State/province [79]
0
0
Incheon
Query!
Country [80]
0
0
Korea, Republic of
Query!
State/province [80]
0
0
Seoul
Query!
Country [81]
0
0
Malaysia
Query!
State/province [81]
0
0
Kuala Lumpur
Query!
Country [82]
0
0
Mexico
Query!
State/province [82]
0
0
Ciudad de Mexico
Query!
Country [83]
0
0
Netherlands
Query!
State/province [83]
0
0
Amsterdam
Query!
Country [84]
0
0
Netherlands
Query!
State/province [84]
0
0
Maastricht
Query!
Country [85]
0
0
Netherlands
Query!
State/province [85]
0
0
Rotterdam
Query!
Country [86]
0
0
Peru
Query!
State/province [86]
0
0
Lima
Query!
Country [87]
0
0
Poland
Query!
State/province [87]
0
0
Gdansk
Query!
Country [88]
0
0
Poland
Query!
State/province [88]
0
0
Krakow
Query!
Country [89]
0
0
Poland
Query!
State/province [89]
0
0
Otwock
Query!
Country [90]
0
0
Poland
Query!
State/province [90]
0
0
Lódz
Query!
Country [91]
0
0
Romania
Query!
State/province [91]
0
0
Bucuresti
Query!
Country [92]
0
0
Romania
Query!
State/province [92]
0
0
Iasi
Query!
Country [93]
0
0
Russian Federation
Query!
State/province [93]
0
0
Barnaul
Query!
Country [94]
0
0
Russian Federation
Query!
State/province [94]
0
0
Ekaterinburg
Query!
Country [95]
0
0
Russian Federation
Query!
State/province [95]
0
0
Kemerovo
Query!
Country [96]
0
0
Russian Federation
Query!
State/province [96]
0
0
Moscow
Query!
Country [97]
0
0
Russian Federation
Query!
State/province [97]
0
0
Novosibirsk
Query!
Country [98]
0
0
Russian Federation
Query!
State/province [98]
0
0
St Petersburg
Query!
Country [99]
0
0
Russian Federation
Query!
State/province [99]
0
0
Tomsk
Query!
Country [100]
0
0
Serbia
Query!
State/province [100]
0
0
Belgrade
Query!
Country [101]
0
0
Singapore
Query!
State/province [101]
0
0
Singapore
Query!
Country [102]
0
0
Slovakia
Query!
State/province [102]
0
0
Bratislava
Query!
Country [103]
0
0
Slovakia
Query!
State/province [103]
0
0
Košice
Query!
Country [104]
0
0
Spain
Query!
State/province [104]
0
0
Barcelona
Query!
Country [105]
0
0
Spain
Query!
State/province [105]
0
0
Madrid
Query!
Country [106]
0
0
Sweden
Query!
State/province [106]
0
0
Goteborg
Query!
Country [107]
0
0
Sweden
Query!
State/province [107]
0
0
Linköping
Query!
Country [108]
0
0
Sweden
Query!
State/province [108]
0
0
Umea
Query!
Country [109]
0
0
Sweden
Query!
State/province [109]
0
0
Uppsala
Query!
Country [110]
0
0
Switzerland
Query!
State/province [110]
0
0
Basel
Query!
Country [111]
0
0
Switzerland
Query!
State/province [111]
0
0
Bern
Query!
Country [112]
0
0
Switzerland
Query!
State/province [112]
0
0
Genève 14
Query!
Country [113]
0
0
Switzerland
Query!
State/province [113]
0
0
Lausanne
Query!
Country [114]
0
0
Taiwan
Query!
State/province [114]
0
0
Kaohsiung
Query!
Country [115]
0
0
Taiwan
Query!
State/province [115]
0
0
Taipei
Query!
Country [116]
0
0
Thailand
Query!
State/province [116]
0
0
Khon Kaen
Query!
Country [117]
0
0
Turkey
Query!
State/province [117]
0
0
Adana
Query!
Country [118]
0
0
Turkey
Query!
State/province [118]
0
0
Istanbul
Query!
Country [119]
0
0
Turkey
Query!
State/province [119]
0
0
Izmir
Query!
Country [120]
0
0
Ukraine
Query!
State/province [120]
0
0
Dnipro
Query!
Country [121]
0
0
Ukraine
Query!
State/province [121]
0
0
Kharkiv
Query!
Country [122]
0
0
Ukraine
Query!
State/province [122]
0
0
Kyiv
Query!
Country [123]
0
0
Ukraine
Query!
State/province [123]
0
0
Lviv
Query!
Country [124]
0
0
United Kingdom
Query!
State/province [124]
0
0
Glasgow
Query!
Country [125]
0
0
United Kingdom
Query!
State/province [125]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Actelion
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)
Query!
Trial website
https://clinicaltrials.gov/study/NCT01112306
Query!
Trial related presentations / publications
Galie N, Gaine S, Channick R, Coghlan JG, Hoeper MM, Lang IM, McLaughlin VV, Lassen C, Rubin LJ, Hsu Schmitz SF, Sitbon O, Tapson VF, Chin KM. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. Adv Ther. 2022 Jan;39(1):796-810. doi: 10.1007/s12325-021-01898-1. Epub 2021 Oct 30.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Aline Frey
Query!
Address
0
0
Actelion
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/06/NCT01112306/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/06/NCT01112306/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01112306
Download to PDF